Armetheon Receives $24,300,000 Series B Funding

  • Feed Type
  • Date
    2/5/2015
  • Company Name
    Armetheon
  • Mailing Address
    3375 Scott Blvd. Santa Clara, CA 95054 USA
  • Company Description
    Armetheon, Inc., is a privately held San Francisco Bay area based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need in cardiovascular diseases. The company was founded by three successful biotech entrepreneurs and pharmaceutical executives with several years of drug R&D and company building experience.
  • Website
    http://www.armetheon.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $24,300,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The company intends to use the funds to advance its lead clinical candidate, tecarfarin, which is being investigated as a novel vitamin-K-antagonist (VKA) oral anticoagulant that avoids adverse drug reactions associated with the current standard-of-care, warfarin
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy